Skip to main content

Table 2 Absolute and relative percent changes in primary and secondary endpoints relative to baseline over follow-up

From: Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study

 

Visit 3 (after chemo)

Visit 5 (6-month follow-up)

GLS

 Absolute change (%)

0 (-2, 1)

1 (-1, 2)

 Relative change (%)

0.0 (-6.3, 10.5)

-4.3 (-10.0, 4.5)

NT-proBNP

 Absolute change (pg/mL)

66.9 (30.4, 138.5)

18.9 (-5.0, 42.1)

 Relative change (%)

217 (86, 551)

67 (-5, 221)

TnI

 Absolute change (ng/dL)

0.00 (0.00, 0.00)

0.00 (0.00, 0.00)

 Relative change (%)

0 (0, 0)

0 (0, 0)

hs-CRP

 Absolute change (mg/L)

-0.12 (-4.01, 1.16)

-2.75 (-6.06, 0.17)

 Relative change (%)

-8.2 (-52.9, 66.8)

-53.9 (-74.2, 21.9)

  1. Primary endpoint: GLS
  2. Secondary endpoints: NT-proBNP, TnI, and hs-CRP
  3. Abbreviations: GLS Left ventricular global longitudinal strain, hs-CRP High-sensitivity C-reactive protein, NT-proBNP N-terminal pro B-type natriuretic peptide, suPAR Soluble urokinase plasminogen activator receptor, TnI Conventional troponin-I